Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series

Lucas Elms, Scott Shannon, Shannon Hughes, Nicole Lewis, Lucas Elms, Scott Shannon, Shannon Hughes, Nicole Lewis

Abstract

Objectives: Cannabidiol (CBD) is a non-psychotomimetic cannabinoid compound that is found in plants of the genus Cannabis. Preclinical research has suggested that CBD may have a beneficial effect in rodent models of post-traumatic stress disorder (PTSD). This effect is believed to be due to the action of CBD on the endocannabinoid system. CBD has seen a recent surge in research regarding its potential value in a number of neuro-psychiatric conditions. This is the first study to date examining the clinical benefit of CBD for patients with PTSD.

Methods: This retrospective case series examines the effect of oral CBD administration on symptoms of PTSD in a series of 11 adult patients at an outpatient psychiatry clinic. CBD was given on an open-label, flexible dosing regimen to patients diagnosed with PTSD by a mental health professional. Patients also received routine psychiatric care, including concurrent treatment with psychiatric medications and psychotherapy. The length of the study was 8 weeks. PTSD symptom severity was assessed every 4 weeks by patient-completed PTSD Checklist for the DSM-5 (PCL-5) questionnaires.

Results: From the total sample of 11 patients, 91% (n = 10) experienced a decrease in PTSD symptom severity, as evidenced by a lower PCL-5 score at 8 weeks than at their initial baseline. The mean total PCL-5 score decreased 28%, from a mean baseline score of 51.82 down to 37.14, after eight consecutive weeks of treatment with CBD. CBD was generally well tolerated, and no patients discontinued treatment due to side effects.

Conclusions: Administration of oral CBD in addition to routine psychiatric care was associated with PTSD symptom reduction in adults with PTSD. CBD also appeared to offer relief in a subset of patients who reported frequent nightmares as a symptom of their PTSD. Additional clinical investigation, including double-blind, placebo-controlled trials, would be necessary to further substantiate the response to CBD that was observed in this study.

Keywords: PTSD; anxiety; cannabidiol; cannabis; nightmares; post-traumatic stress disorder.

Conflict of interest statement

S.S., MD has published four professional books in the area of Integrative Mental Health. Dr. S.S. is a Principal Investigator for a Phase III study of MDMA assisted psychotherapy for severe PTSD and receives compensation for his clinical work from a nonprofit corporation, the Multidisciplinary Association for Psychedelic Studies. Dr. S.H., Dr. N.L., and Mr. L.E. report no competing financial interests.

Figures

FIG. 1.
FIG. 1.
Mean PCL-5 score of the sample over the course of the study depicted as a function of time showing the observed decrease. PCL-5, Post-Traumatic Stress Disorder Checklist for the DSM-5.

References

    1. Goldstein RB, Smith SM, Chou SP, et al. . The epidemiology of DSM-5 posttraumatic stress disorder in the United States: Results from the National Epidemiologic Survey on alcohol and related conditions-III. Soc Psychiatry Psychiatr Epidemiol 2016;51:1137–1148
    1. Parsons RG, Ressler KJ. Implications of memory modulation for post-traumatic stress and fear disorders. Nat Neurosci 2013;16:146–153
    1. Marsicano G, Wojtak CT, Azad SC, et al. . The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002;418:530–534
    1. Campos AC, Moreira FA, Gomes FV, et al. . Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 2012;367:3364–3378
    1. Ibeas Bih C, Chen T, Nunn AV, et al. . Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 2015;12:699–730
    1. Zanelati TV, Biojone C, Moreira FA, et al. . Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors. Br J Pharmacol 2010;159:122–128
    1. Bergamaschi MM, Queiroz RH, Chagas MH, et al. . Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36:1219–1226
    1. Zuardi AW, Rodrigues NP, Silva AL, et al. . Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 2017;11;8:259
    1. Zuardi AW, Cosme RA, Graeff FG, Guimarães FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 1993;7 (1Suppl):82–88
    1. Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 1990;100:558–559
    1. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199–215
    1. De Petrocellis L, Ligresti A, Moriello AS, et al. . Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163:1479–1494
    1. Stern CA, Gazarini L, Takahashi RN, et al. . On disruption of fear memory by reconsolidation blockade: Evidence from cannabidiol treatment. Neuropsychopharmacology 2012;37:2132–2142
    1. Bitencourt RM, Pamplona FA, Takahashi RN. Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol 2008;18:849–859
    1. Chhatwal JP, Davis M, Maguschak KA, Ressler KJ. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 2005;30:516–524
    1. Shannon S, Oplia-Lehman J. Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: A case report. Perm J 2016;20:108–111
    1. Das RK, Kamboj SK, Ramadas M, et al. . Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl) 2013;226:781–792
    1. Bitencourt RM, Takahashi RN. Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: From bench research to confirmation in human trials. Front Neurosci 2018;12:502.
    1. Weather FW, Litz BT, Keane TM, et al. . The PTSD checklist for DSM-5 (PCL-5) [homepage on the Internet]. National Center for PTSD. Online document at: , accessed September7, 2018
    1. Blevins CA, Weathers FW, Davis MT, et al. . The posttraumatic stress disorder checklist for DSM-5 (PCL-5): Development and initial psychometric evaluation. J Trauma Stress 2015;28:489–498

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit